Histogen — Conatus Pharmaceuticals — Corporate Update (May 2019)
27 slides from Histogen's corporate update, May 15, 2019
Slide 1: Inflammasome Program
May 2019 Inflammasome Program Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products,
Slide 3: Highlights of Conatus Approach
Highlights of Conatus Approach Like inflammasome intervention, caspase 1 inhibition is a small molecule strategy to block the formation of IL-1b Additional benefits include IL-18 inhibition, gasdermin D inhibition, and a decrease in inflammation driven cell death (pyroptosis) vs. IL-1b blocking agen
Slide 4: IL-1β Blocking Agents: Set the Stage for Next Generation Products
IL-1β Blocking Agents: Set the Stage for Next Generation Products Multiple approved biologic agents that block IL-1β Canakinumab (Ilaris ®) monoclonal antibody targeted at IL-1β Anakinra (Kineret ®) interleukin-1 receptor antagonist Rilonacept (Arcalyst ®) IL-1 Trap Global sales of over $700 million
Slide 5: IL-1b: Driven by Multiple Inflammasomes
IL-1b: Driven by Multiple Inflammasomes Solberger G, et al. Innate Immun. 2014, p115-125.
Slide 6: Disease Areas Implicated in the Inflammasome Pathway
Disease Areas Implicated in the Inflammasome Pathway Therapeutic areas Disease Conditions Autoinflammatory Cryopyrin-Associated Periodic Syndromes Muckle-Wells Syndrome Schnitzler’s Syndrome Familial Mediterranean Fever Macrophage Activation Syndrome Gastroenterology Crohn's Ulcerative Colitis IBD R
Slide 7: IL-1b Blocking Agents: Development Pathway Defined
IL-1b Blocking Agents: Development Pathway Defined* Wide scope of clinical indications and therapeutic validation All agents given by injection (not orally active) Most recent success – Novartis, Ilaris® 2017: Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) Confidential Kineret® Ilar
Slide 8: The Future of IL-1β Blocking May Be in Cancer
The Future of IL-1β Blocking May Be in Cancer
Slide 9: Inflammasome Companies: Investor and Pharma Interest
Inflammasome Companies: Investor and Pharma Interest IFM TRE raised a $31mm Series A in 2018 from Atlas, Abingworth, and BMS. Acquisition by Novartis announced April 2019 for $310M upfront (Phase 1) and up to $1.6B total. Jecure Therapeutics raised a $30mm Series A from Versant in 2017. Acquired by
Slide 10: Caspase 1 Inhibitors Target Inflammasome Pathway at Optimal Intervention Point
(Novartis) (Amgen) (Regeneron) Caspase 1 Inhibitors Caspase 1 Inhibitors Target Inflammasome Pathway at Optimal Intervention Point We believe a caspase 1 selective small molecule inhibitor can be a safe and efficacious agent for intervention in the inflammasome pathway Modified from Mangan M et al.
Slide 11: Caspase Inhibition Improves Survival Better than Blocking IL-1β, IL-18 or Both
Caspase 1 Inhibition Improves Survival Better than Blocking IL-1β, IL-18 or Both Constitutively active NLRP3 (FCAS model) results in chronic activation of caspase 1 Leads to production of IL-1β and IL-18 Leads to pyroptotic cell death via gasdermin D cleavage Caspase 1 KO showed improved survival ov
Slide 12: Targeting IL-1b and Inflammation via Caspase Inhibition
Targeting IL-1b and Inflammation via Caspase 1 Inhibition IL-1b is a validated inflammatory target – high interest in the pathway NLRP3 Caspase 1 IL-1β Pro caspase 1 Pro IL-1β Inflammation NLRP3 companies Biologic products (Novartis) (Amgen) (Regeneron) “Detector” senses stress signal “Master” infla
Slide 13: CTS-2090 Bridging the gap between Detector and Master
CTS-2090 Bridging the gap between “Detector” and “Master”
Slide 14: Conatus' Caspase Inhibitor Portfolio
Conatus’ Caspase 1 Inhibitor Portfolio Designed highly selective caspase 1 inhibitors Incorporated novel chemistry to remove activity against apoptotic caspases Maintained sub-nanomolar activity against caspase 1 Inhibits downstream IL-1b (a clinically validated target) Demonstrated functional activ
Slide 15: Conatus' Lead Caspase Inhibitor: CTS-2090
Conatus’ Lead Caspase 1 Inhibitor: CTS-2090 Potency Sub-nanomolar IC50 against human caspase 1 Sub-micromolar IC50 in THP 1 cells Selectivity Broad panel of receptors and enzymes: >100,000 fold selectivity over caspase 1 No anti-apoptotic activity in cells at 10mM: enzyme selectivity reflected in ce
Slide 16: CTS-2090: Enzymatic Potency and Selectivity
CTS-2090: Enzymatic Potency and Selectivity CTS-2090 is a potent, selective and irreversible inhibitor of caspase 1 Additional analogs have similar potency Target: IDN-7314+ CTS-2090 Caspase 1 <5.08E-11 5.60E-11 Caspase 3 1.60E-09 * Caspase 6 2.14E-08 * Caspase 7 4.63E-10 * CTS-2090: IC50 values aga
Slide 17: CTS-2090: Potency and Selectivity Validated in Cell-based Functional Assays
CTS-2090: Potency and Selectivity Validated in Cell-based Functional Assays CTS-2090 is a potent inhibitor of LPS-stimulated NLRP3 driven IL-1b production in THP 1 cells IC50 value similar to that of the reference pan-caspase inhibitor, IDN-7314 CTS-2090 does not protect Jurkat cells from a-Fas – in
Slide 18: CTS-2090: Not Active in an Animal Model of Apoptosis
CTS-2090: Not Active in an Animal Model of Apoptosis In vivo activity is consistent with cellular and enzymatic selectivity profiles CTS-2090 does not protect against apoptosis induced by aFas in mice IDN-7314 is completely protective against aFas induced apoptosis in mice CTS-2090 (10 mg/Kg) and ID
Slide 19: CTS-2090: Reduces IL-1b and IL-18 in an NLRP3 Driven Inflammasome Model
CTS-2090: Reduces IL-1b and IL-18 in an NLRP3 Driven Inflammasome Model CTS-2090 reduces IL-1b and IL-18 similar to MCC950 in an NLRP3 activation model of peritonitis CTS-2090 and MCC950 were administered i.p. 1 hour post-LPS injection At 2h post-LPS, ATP was administered and 30 min. later peritonea
Slide 20: CTS-2090: Reduces IL-1b in the MSU Crystal-Induced Gout Model
CTS-2090: Reduces IL-1b in the MSU Crystal-Induced Gout Model CTS-2090 (10mg/Kg) reduced IL-1b similar to MCC950 (40mg/Kg) CTS-2090 and MCC950 were administered i.p. 30 min. prior to MSU Peritoneal lavage fluid was collected 6h post-MSU injection and analyzed for IL-1b * * Percent reduction *
Slide 21: CTS-2090: Tissue Distribution and Metabolic Stability
Intestine Liver tissue CTS-2090: Tissue Distribution and Metabolic Stability Good oral bioavailability: 45% in rodent Higher tissue distribution of parent molecule in colon than plasma or liver ~1:1 distribution plasma / liver Excellent metabolic stability in rodent tissue (liver and intestine)
Slide 22: CTS-2090: Reduces Disease Severity in the Rat TNBS Colitis Model
CTS-2090: Reduces Disease Severity in the Rat TNBS Colitis Model CTS-2090 reduces TNBS-induced weight loss as effectively as prednisolone at day 7 Oral administration of CTS-2090 or Prednisolone initiated 1 day post-TNBS induced colitis and dosed for 6 days. Animal weights monitored daily
Slide 23: Autoinflammatory Diseases as Initial Clinical Target for CTS-2090
Autoinflammatory Diseases as Initial Clinical Target for CTS-2090 Single-gene mutations that activate inflammasomes and result in IL-1β production Spectrum of diseases with variable organ system involvement, severity and age of onset Cryopyrin-associated periodic syndromes (CAPS) Familial cold urtic
Slide 24: Overview of CTS-2090 Development Plan
Overview of CTS-2090 Development Plan Phase 1, part A Single-dose PK Phase 1, part B Multiple-dose PK Phase 2a Multiple-dose/endotoxin challenge study in normal volunteers Phase 2 PoC Autoinflammatory Diseases Other Potential Indications IBD/Crohn’s Gout flares Oncology PK, Safety, Tolerability Dose
Slide 25: Intellectual Property
Intellectual Property Two new composition of matter provisional patent applications filed Applications describe two broad and distinct non-overlapping chemical series of inhibitors Additional novel chemical classes have been identified. New provisional applications planned.
Slide 26: Highlights of Conatus Approach
Highlights of Conatus Approach Like inflammasome intervention, caspase 1 inhibition is a small molecule strategy to block the formation of IL-1b Additional benefits include IL-18 inhibition, gasdermin D inhibition, and a decrease in inflammation driven cell death (pyroptosis) vs. IL-1b blocking agen
Slide 27: Conatus Pharmaceuticals
Conatus Pharmaceutical
Conatus Pharmaceuticals — Corporate Update (May 2019) on 6ix